News | Hypertension | September 10, 2015

Sunshine Heart Initiates C-Pulse Animal Study for Pulmonary Arterial Hypertension Treatment

If successful, technology would offer therapeutic options for patient population that currently has no approved treatments

September 10, 2015 — Sunshine Heart Inc. announced commencement of a new study examining the impact of the C-Pulse system on pulmonary circulation and right heart related to pulmonary hypertension and heart failure. The study is a collaborative effort with Mark Slaughter, M.D., and the University of Louisville.

Pulmonary arterial hypertension (PAH) is a debilitating condition characterized by progressive increases in pulmonary vascular resistance and loss of elasticity of the pulmonary artery and large vessels. Patients with PAH suffer from poor quality of life, shortness of breath and greatly reduced functional capacity leading to right ventricular dysfunction and ultimately, right heart failure. PAH afflicts approximately 200,000 patients worldwide and places a significant burden on the healthcare system, with limited treatment options available and five-year survival rates as low as 34 percent. PAH and right heart failure are also commonly associated with left heart failure. Approximately 50 percent of patients with systolic heart failure or preserved ejection fraction heart failure (HFpEF) have PAH with similar five-year outcomes. PAH and right heart failure also continue to remain a significant risk in the left ventricular assist device patient population.

These studies hope to provide scientific rationale for a new application of current C-Pulse therapy by leveraging the existing technology to apply counterpulsation to the pulmonary artery in acute and chronic animal preparations. Biochemical, neurohormonal, and pressure-volume data will be used to assess the effects of C-Pulse on pulmonary circulation and right and left heart properties. A fully implantable system may provide therapeutic options in HFpEF populations with PAH where there are currently no approved treatments.

For more information: www.sunshineheart.com

Related Content

Petaluma Health Center Wins 2017 HIMSS Davies Award for Hypertension Control Program
News | Hypertension | February 16, 2018
February 16, 2018 — California’s Petaluma Health Center (PHC) was recently awarded a 2017 Healthcare Information and
SPRINT Trial Data Support New AHA/ACC Hypertension Guidelines
News | Hypertension | November 16, 2017
Findings from a landmark study funded by the National Institutes of Health (NIH) support a key component of the new...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension | September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Text Messaging Could Help Tackle High Blood Pressure in At-Risk Patients

Image courtesy of Michigan Medicine

News | Hypertension | September 06, 2017
A new National Institutes of Health-funded hypertension trial will examine the possibility of using an emergency...
MobiusHD Device Shows Promise in Treatment of Resistant Hypertension
News | Hypertension | August 30, 2017
Vascular Dynamics Inc. announced interim results of the company’s first-in-human trial of its MobiusHD implant...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension | August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Bayer Now Enrolling Patients for Global Pulmonary Arterial Hypertension Study
News | Hypertension | July 05, 2017
Bayer has enrolled the first patient in a global Phase IV study assessing the clinical effects of riociguat in patients...
USC Study Finds Potassium-Rich Diet Can Lower Blood Pressure
News | Hypertension | April 19, 2017
Eating potassium-rich foods like sweet potatoes, avocados, spinach, beans, bananas and even coffee could be key to...
Vascular Dynamics Completes $10.4 Million Financing for MobiusHD System
News | Hypertension | April 13, 2017
Vascular Dynamics Inc. (VDI) a privately held medical device company developing novel solutions for the treatment of...
online lifestyle intervention, systolic blood pressure, hypertension, ACC.17, clinical study
News | Hypertension | March 27, 2017
Participants in Web-based lifestyle counseling reduced their systolic blood pressure by 10 mmHg, compared with a 6 mmHg...
Overlay Init